Vyvgart Hytrulo is FDA-approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It is given once a week as a shot under the skin.

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PR Newswire SAN ...

SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products ...

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the ...

SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human ...

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ...

CIDP denotes chronic inflammatory demyelinating polyneuropathy, Covid-19 coronavirus disease 2019, and HDFN hemolytic disease of the fetus and newborn. Efgartigimod is approved for treatment in ...

VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. There is increasing evidence that IgG antibodies play a key role ...

--Halozyme Therapeutics, Inc. today announced that argenx received European Commission approval of VYVGART ® 1000 mg developed with ENHANZE ®, Halozyme's proprietary recombinant human ...